Contributors

   

Walter C. Low

Dr. Walter Low is a Professor in the Department of Neurosurgery and serves as the Associate Head for Research. He earned his Ph.D. in Bioengineering/Neurophysiology from the University of Michigan, and was an NSF/NATO postdoctoral fellow in Neurophysiology at Cambridge University, England. He is currently the Director of the Research Laboratories in the Department of Neurosurgery.

Dr. Low was formerly on the faculty at the Indiana University School of Medicine where he was Director of the Graduate Program in Physiology and Biophysics. He has served as a member of grant review study sections for the NINDS, NIGMS, and the National Science Foundation.

He was a recipient of an Individual National Research Service Award from the National Institutes of Health, an Established Investigator Award from the American Heart Association, and a University of California Alumni Scholar Award.

He has provided editorial service for the journals Science, Trends in Neuroscience, Brain Research Bulletin, Experimental Neurology, Cell Transplantation, Molecular and Cellular Neuroscience, American Journal of Physiology, Neuroscience, Physiology and Behavior, Canadian Journal of Zoology, Restorative Neurology and Neuroscience, Journal of the Autonomic Nervous System, and the International Journal of Neuroscience.

He is a founding member of the American Society for Neural Transplantation (ASNT), and served as President-Elect for the society from 2005-2006. He currently serves as a member of the Clinical Practice Committee for the ASNT. Dr. Low's research is focused on the use of stem cells for the treatment of neurological disorders such as Parkinson's disease. Research in the area of cell therapy involves the use of neural transplants to repair neural connections in neurodegenerative disorders such as Parkinson's disease. Dr. Low's laboratory is also focused on the study of brain tumors. Primary tumors that originate in the brain represent some of the most malignant types of cancers. Patients diagnosed with grade IV glioblastoma multiforme have a mean survival time of 11 months after diagnosis. Our studies of brain tumors have emphasized the development of immunotherapeutic approaches for the treatment of these tumors. Cancer vaccines consisting of cytokines and tumor antigens are used to stimulate cells of the immune system to recognize and destroy tumors within the brain.

Website Builder